| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Shi,Ying-Zhu | Chairman | 3.05% | |
| Cai,Wei-Cheng | Director | 3.74% | |
| Yuan,Hong-Chang | Director | 0.09% | |
| Yang,Qing-Hua | Director | 0.00% | |
| Li,Jia-Rong | Director | 2.60% | |
| Zheng,Ming-Yuan | Independent Director | 0.00% | |
| Gao,Xiu-Qing | Independent Director | 0.00% | |
| Su,Rong-Cheng | Independent Director | 0.00% |
Change Company Name to TAIWANJ PHARMACEUTICALS, CO., LTD.
2024/06/17
Change Capital to 1,500,000,000
2023/06/19
Change Company Name to JINGKAI BIOTECHNOLOGY CO., LTD. (FORMER NAME: TAIWAN JINGKAI BIOTECHNOLOGY CO., LTD.)
2022/10/07
Change Capital to 1,000,000,000
2018/03/16
Change Person in Charge to Shi,Ying-Zhu
2017/10/27
Change Person in Charge to Chen,Jian-Zhang
2017/06/16
Change Capital to 600,000,000
2015/01/07
Change Capital to 400,000,000
2014/02/07
Change Company Name to TAIWANJ PHARMACEUTICALS, CO., LTD.
2013/10/21
Change Capital to 100,000,000
2012/11/21
下載完整報告查看完整數據
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 0 | 22,742 | 15,355 |
| Operating cost | - | 0 | 75,277 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 0 | 22,742 | -59,922 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 0 | 22,742 | -59,922 |
| Operating expenses | 26,956 | 29,352 | 36,472 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -26,956 | -6,610 | -96,394 |
| Non-operating income and expenses | 4,615 | 2,837 | 3,927 |
| Net profit (loss) before tax | -22,341 | -3,773 | -92,467 |
| Income tax expense (benefits) | 0 | 2,274 | 0 |
| Net profit (loss) of ongoing business for the current period | -22,341 | -6,047 | -92,467 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -22,341 | -6,047 | -92,467 |
| Other comprehensive profit (loss), net | - | - | - |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -22,341 | -6,047 | -92,467 |
| Net profit (loss) attributable to owners of parent company | - | - | - |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | - | - | - |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | 0 | -1 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | - | - | - |
| Net cash inflows (outflows) from investing activities | - | - | - |
| Net cash inflow (outflow) from financing activities | - | - | - |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | - | - | - |
| Beginning balance of cash and cash equivalents | - | - | - |
| Ending balance of cash and cash equivalents | - | - | - |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 93,182 | 64,085 | 71,171 |
| Non-current asset | 7,584 | 9,473 | 8,618 |
| Total asset | 100,766 | 73,558 | 79,789 |
| Current liability | 5,713 | 6,146 | 7,015 |
| Non-current liability | 0 | 472 | 1,170 |
| Total liability | 5,713 | 6,618 | 8,185 |
| share capital | 801,220 | 751,220 | 751,220 |
| Equity - secruity token | - | - | - |
| capital reserve | 2,425 | 1,971 | 588 |
| retained earning | -708,592 | -686,251 | -680,204 |
| Other equity | - | 0 | 0 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | - | - | - |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 95,053 | 66,940 | 71,604 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 1 | 0 | 0 |
